Three-ring PI3K and/or mTOR inhibitor

A compound of general formula (I):

• or a pharmaceutically acceptable salt, ester, solvate or stereoisomer thereof,
• wherein
• X is O or S;
• A and B are each CR8, R8 is hydrogen, halogen, cyano, hydroxy, carboxyl, —(CH2)nNR10aR10b, —(CH2)nC(O)R11, —(CH2)nS(O)mR11, —(CH2)nS(O)mNR10aR10b, —(CH2)nN(R10a)S(O)mR11, —(CH2)nC(O)NR10aR10b, —(CH2)nOC(O)R11, —(CH2)nC(O)(CH2)nOR11, —(CH2)nN(R10a)C(O)R11, C1-6 alkyl or C1-6 alkoxy, wherein C1-6 alkyl and C1-6 alkoxy may be optionally substituted with 1 to 3 substituents selected from halogen, hydroxy and carboxyl;
• R1 is (trifluoromethyl)phenyl;
• R2 is hydrogen, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 cycloalkyl, 6- to 14-membered aryl, 5- to 14-membered heteroaryl, 3- to 14-membered heterocyclic group, 7- to 12-membered spirocyclic group or 7- to 12-membered endocyclic group, all of which except hydrogen may be optionally substituted with 1 to 5 R9b;
• R3 is hydrogen, carboxyl or C1-6 alkyl, wherein C1-6 alkyl may be optionally substituted with 1 to 3 substituents selected from halogen, hydroxy and carboxyl;
• R4 and R5 are each independently hydrogen or C1-6 alkyl, wherein C1-6 alkyl may be optionally substituted with 1 to 3 substituents selected from halogen, hydroxy and carboxyl;
• or R4 and R5 combine each other to form C3-8 cycloalkyl, 5- to 6-membered monocyclic heteroaryl or 5- to 6-membered monocyclic heterocyclic group;
• R6 is hydrogen or C1-6 alkyl, wherein C1-6 alkyl may be optionally substituted with 1 to 3 substituents selected from halogen, hydroxy and carboxyl;
• R9b is
• (1) halogen, cyano, hydroxy, —(CH2)nNR10aR10b, —(CH2)nC(O)R11, —(CH2)nS(O)mR11, —(CH2)nS(O)mNR10aR10b, —(CH2)nN(R10a)S(O)mR11, —(CH2)nC(O)NR10aR10b, —(CH2)nOC(O)R11, —(CH2)nC(O)(CH2)nOR11, —(CH2)nN(R10a)C(O)R11;
• (2) C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl or C1-6 alkoxy, all of which may be optionally substituted with 1 to 3 substituents selected from halogen, hydroxy and cyano;
• (3) C3-8 cycloalkyl, 6- to 14-membered aryl, 5- to 14-membered heteroaryl or 3- to 14-membered heterocyclic group, all of which may be optionally substituted with 1 to 3 substituents selected from halogen, hydroxy, cyano, trifluoromethyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-6 alkoxy, —(CH2)nNR10aR10b, —(CH2)nC(O)R11, —(CH2)nC(O)NR10aR10b, —(CH2)nS(O)mR11, —(CH2)nS(O)mNR10aR10b, —(CH2)nN(R10a)S(O)mR11, —(CH2)nOC(O)R11 and —(CH2)nN(R10a)C(O)R11;
• R10a and R10b are each independently hydrogen, C1-6 alkyl, C3-8 cycloalkyl, 6- to 14-membered aryl, 5- to 14-membered heteroaryl or 3- to 14-membered heterocyclic group, all of which except hydrogen may be optionally substituted with 1 to 3 substituents selected from hydroxy, halogen, cyano, carboxyl, —(CH2)nNR10aR10b, sulfamoyl, carbamoyl and sulfamino;
• R11 is hydrogen, C1-6 alkyl or C1-6 alkoxy, wherein C1-6 alkyl and C1-6 alkoxy may be optionally substituted with 1 to 3 substituents selected from halogen, cyano, hydroxy, carboxyl, —(CH2)nNR10aR10b, sulfamoyl and carbamoyl;
• m is 0, 1 or 2;
• and
• n is 0-4.